This is a routine procedural ruling with no material impact on Moderna's stock. The underlying patent litigation continues on its existing schedule. Monitor for claim construction rulings or summary judgment motions later in 2026, which would carry substantive risk.
Price Chart
Executive Summary
A Special Master in the District of Delaware denied GSK's motion to limit third-party inventor depositions to 10 combined hours across its patent infringement cases against Pfizer/BioNTech and Moderna. The ruling allows each defendant group up to 7 hours per inventor witness, preserving full examination rights for key inventors Dr. Geall and Dr. Mandl. This is a procedural discovery ruling with no financial exposure, no injunction, and no change to the underlying patent litigation merits.
Court Ruling Details
Key Facts
- GSK's motion to limit defendants to 10 combined hours of third-party inventor depositions was DENIED
- Each defendant group (Pfizer/BioNTech and Moderna) retains the right to up to 7 hours per inventor witness under FRCP 30(d)(1)
- The ruling concerns two key witnesses: Dr. Andrew Geall (named inventor on all asserted patents) and Dr. Christian Mandl
- Fact discovery closes July 29, 2026, in all three related actions
- No damages, injunction, or liability determination was made — purely a scheduling/discovery dispute
Financial Impact
No financial impact — procedural discovery ruling only
Risk Factors
- No new risks from this ruling — the underlying patent infringement cases remain pending with no liability determination
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3rrqn0ol-MRNA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 2d ago | ANALYST-DOWNGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | ANALYST-DOWNGRADE | $148.87 $143.97 | ▲ +3.29% | ▲ +2.14% | $190.01 (−27.63%) |
Aug 31, 2026 4w ago | Court Ruling | $140.19 $140.33 | ▼ −0.10% | ▼ −0.24% | $190.01 (−35.54%) |
Aug 25, 2026 5w ago | ANALYST-UPGRADE | $158.83 $154.27 | ▼ −2.87% | ▼ −2.33% | $190.01 (+19.63%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $174.38 $149.66 | ▼ −14.18% | ▼ −13.79% | $190.01 (+8.96%) |
Aug 5, 2026 8w ago | 144 | $56.26 $63.67 | ▼ −13.18% | ▼ −12.83% | $190.01 (−237.77%) |
Jul 31, 2026 9w ago | 8-K | $54.82 $59.17 | ▲ +7.94% | ▲ +4.42% | $190.01 (+246.61%) |
Jul 10, 2026 11w ago | 3 | $67.01 $61.82 | ▼ −7.75% | ▼ −6.96% | $190.01 (+183.55%) |
Jul 8, 2026 12w ago | 8-K | $73.80 $67.44 | ▼ −8.62% | ▼ −9.48% | $190.01 (+157.47%) |
Jun 18, 2026 15w ago | 144 | $63.96 $59.75 | ▼ −6.58% | ▼ −4.92% | $190.01 (+197.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access